Eun Hyun Ahn , PhD
Email: ahneun@uw.edu
Dr. Ahn’s current research interests are focused on: Breast cancer stem cell mutagenesis and DNA repair and microenvironmental regulation of cancer stem cells and carcinogenesis. Dr.Ahn’s previous research areas include: (1) Identification and biochemical characterization of target genes of PAX3-FOXO1 in alveolar rhabdomyosarcoma; (2) Regulation of differentiation of human mesenchymal stem cells and cardiac precursor cells by nanotopography-induced cellular stiffness and rigidity; (3) Roles of retinoic acids and retinoic acid receptorson proliferation, cell cycle, and cell signaling; (4) chemotherapeutic and chemopreventive mechanisms of sphingolipids in colon and breast cancers; Anti-tumorigenic activities of antisense oligonucleotides against AKT1 in various cancer cells.
Katie Albert , MD
Email: Katie.Albert@seattlechildrens.org
Dr. Albert's clinical interests are in pediatric oncology, pediatric sarcomas, pediatric solid tumors, adolescent and young adult oncology. Her research interests are molecular targets in sarcomas and immunotherapy for pediatric solid tumors.
Mike Averkiou , PhD
Email: maverk@uw.edu
Phone: (206) 616-9558
Dr. Averkiou develops new ultrasound imaging and therapy technology for disease detection, improved cancer treatment and monitoring, improved drug delivery to targeted cells, and heart disease. Using advanced nonlinear imaging techniques and microbubble contrast agents, he is able to detect the earliest stages of tumor angiogenesis and atherosclerosis, and closely monitor their treatment. He focuses on transferring innovations from preclinical research into clinical use.
Geoffrey Baird , MD, PhD
Email: gbaird@uw.edu
Phone: (206)744-9787
Dr. Baird's clinical interests include laboratory test utilization, molecular diagnostics, proteomics and immunohistochemistry. His group has developed a new proteomic technology for biomarker discovery in a range of diseases such as malignancies, cardiovascular disorders, and inflammatory conditions. One application of their technology is to discover protein expression changes associated with non-small cell lung cancer that have implications for diagnosis and treatment.
K. Scott Baker , MD
Email: ksbaker@fredhutch.org
Phone: (206) 667-5594
Dr. Baker is a pediatric oncologist. His main focus is on late effects of cancer therapy, in particular in patients that have undergone hematopoietic stem cell transplant for non-malignant disorders such as bone marrow failure syndromes, primary immunodeficiencies, and the histocytic disorders. He is interested in the use of umbilical cord blood for use in transplantation for both malignant and non-malignant diseases.
William Bensinger , MD
Email: wbensing@fredhutch.org
Phone: (206) 667-4933
Dr. Bensinger treats patients with multiple myeloma, amyloidosis, and plasmacytoma. His clinical interests are Autologous Stem Cell Transplantation, Immunotherapy and Targeted Radiotherapy.
C. Anthony (Tony) Blau , MD
Email: tblau@u.washington.edu
Phone: (206) 685-6873
Dr. Blau specializes in orchestrating collaborations across disparate scientific disciplines toward grand goals. As a physician-scientist he believes that our approach to cancer needs to be fundamentally restructured, and for this reason founded the UW's Center for Cancer Innovation (CCI). CCI applies the latest scientific knowledge to the treatment of today's cancer patients while using their experiences to benefit all cancer patients tomorrow. CCI recently launched its first clinical trial in an aggressive form of breast cancer called 'triple-negative' breast cancer. CCI is a grass-roots 'coalition of the willing,' comprised of nearly 100 community and academic oncologists, scientists, computational biologists, and other specialists from six different organizations, and owes much of its success to support from the South Sound region.
Lynn Bonham , PhD
Email: lbonham@seattlecca.org
Phone: (206)288-2022
Dr. Bonham directs and manages Cellular Therapeutics at SCCA, which processes cells from peripheral blood, bone marrow and cord blood for standard transplantations and clinical trials for cancer treatment.
Roger Brent , PhD
Email: rbrent@fredhutch.org
Phone: (206) 667-1482
Dr. Brent studies the quantitative operation of the systems that living cells use to sense, represent, transmit, and act upon information to make decisions that determine their future fates. He specifically studies prototypic cell signaling systems in budding yeast and the pheromone response system; he has extended similar work to systems operating in single cells of tissues in a metazoan, Caenorhabditis elegans.
Mac Cheever , MD
Email: mcheever@fredhutch.org
Phone: (206) 667-4141
Dr. Cheever's specialty is in the areas of medical oncology, immunotherapy and solid tumor research. His current research interests are in conducting cancer clinical trials to develop and test new immunotherapies. He also interested on developing the principles of T cell therapy, cancer antigen discovery and development of cancer vaccines, especially for breast cancer.
Eleanor Chen , MD, PhD
Email: eleanor2@uw.edu
Phone: 206 616-5062
Dr. Chen's main research interest is in understanding pathogenesis of cancer using zebrafish and mammalian experimental systems. Her current research focuses on dissecting cellular and molecular mechanisms underlying pediatric embryonal rhabdomyosarcoma, in particular the key events driving relapse and metastasis. Her laboratory utilizes high-throughput chemical genetic and genomic approaches to identify key driver events of embryonal rhabdomyosarcoma. In addition, by imaging cellular processes in our transgenic zebrafish tumor models, she seeks to dissect key cellular events leading to relapse and metastasis. Her clinical interest is in bone and soft tissue pathology.
Daniel Chiu , PhD
Email: chiu@u.washington.edu
Phone: (206) 543-1655
Dr. Chiu is a professor of engineering at UW whose research focus is on developing and applying single-molecule methods for probing complex biological systems, specifically synaptic functioning and single-cell biology. The Chiu group is interested in studying both the biophysical properties of single proteins in the context of a cell, as well as using the sensitivities achieved in single-molecule detection for biotechnological applications, such as in high-throughput screening, in the separation and detection of trace biological molecules from single cells (e.g., signaling proteins), and in the development of ultrasensitive sensors.
Bonnie Cole , MD
Email: blecole@uw.edu
Phone: (206) 987-2103
Dr. Cole's clinical interests are pediatric pathology and laboratory medicine. She is interested in the genetics of brain tumors and genetic test utilization.
Darin Davidson , MD, MHSc, FRCSC
Email: djdavi@uw.edu
Phone: (206) 543-3690
Dr. Davidson is interested in the management of soft tissue and bone sarcoma, benign soft tissue and bone tumors, clinical epidemiology. His particular research focus relates to quality of life outcomes in the management of bone and soft tissue tumors.
Richard Ellenbogen , MD, FACS
Email: rge@u.washington.edu
Phone: (206) 744-9321
Dr. Ellenbogen's clinical expertise is in pediatric neurological surgery issues and specializes in the care of children with brain tumors, craniofacial disorders, and congenital abnormalities. His adult neurosurgery expertise ranges from brain tumors to craniocerebral trauma. His other areas of interest are: trauma surgery, craniofacial abnormalities, Chiari malformations, congenital spine surgery and minimally invasive brain surgery. He is also conducting research on molecular imaging/nanoparticles and on traumatic brain injury.
Ralph Ermoian , MD
Email: ralphpe@u.washington.edu
Phone: (206) 598-4100
Dr. Ermoian is a radiation oncologist who focuses on pediatric patients with CNS and non-CNS tumors, and transplant-related radiation. His research focuses on outcomes of pediatric patients treated with radiation therapy, transplant medicine and medical education.
Min Fang , MD, PhD
Email: fangm@uw.edu
Phone: (206) 288-1390
Dr. Fang's research focus is on the genomics and combinatorial genetics/epigenetics of human neoplasia. She is combining classical genetic approaches of mapping, karyotyping, and functional genetics with new genomic tools including microarray, comparative genome hybridization, and next-generation sequencing, to identify genetic and epigenetic aberrations in cancer that may serve as actionable biomarkers for treatment decision making for individual patients.
Jesse Fann , MD, PhD
Email: fann@u.washington.edu
Phone: (206) 685-4280
Dr. Fann is a psychiatrist with clinical expertise in neuropsychiatry and psycho-Oncology. His areas of research include the epidemiology, health services implications, and treatment of psychiatric aspects of cancer, traumatic brain injury, and spinal cord injury.
Manuel Ferreira , MD, PhD
Email: manuelf3@u.washington.edu
Phone: (206) 744-932
Dr. Ferreira specializes in the multi-modality treatment for tumors of the skull base, brain and spinal cord, including meningiomas; schwannomas; pituitary tumors; craniopharyngiomas; neurofibromatosis; chordomas and chondrosarcomas; Von Hippel-Lindau; hemangioblastomas; sinonasal tumors of the skull base; and cysts. He uses minimally-invasive skull base procedures to treat these conditions. Moreover he conducts research to understand the genetic basis of these tumors and inherited disorders and wants to use the genetic discovery to predict response to therapy (radio-sensitivity or radio-resistance).
Albert Folch , PhD
Email: afolch@u.washington.edu
Phone: (206) 685-2257
Dr. Folch's mission is to develop miniature cell culture tools for quantitative neurobiology studies. In particular, the use of microfabrication techniques and nanotechnology. The goal of his group is to develop the next generation of microfluidic devices for applications in automated cell culture, neuroscience research, cancer diagnostics, and cancer therapy. They have also developed microfluidic patch clamp chips for recording the electrophysiological activity of suspension cell lines such as rat basophilic leukemia (RBL) cells.